SBIR Phase II: A Novel Bacteriophage Mutant as a Platform Carrier for Next Generation Vaccines

SBIR II 期：一种新型噬菌体突变体作为下一代疫苗的平台载体

• 批准号: 2150936
• 负责人: Herbert Kavunja
• 金额: $ 97.86万
• 依托单位: IASO THERAPEUTICS, INC.
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2150936&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Novel; Bacteriophage

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the contribution to the field of conjugate vaccines, which have made revolutionary and tremendous contributions to public health. When successfully developed, the proposed platform will be available for use by biotechnology and pharmaceutical companies to develop next-generation conjugate vaccines against a wide range of antigens, including cancer and emerging infectious diseases, for improved clinical outcomes. In addition to vaccines, the platform offers an excellent starting point for the generation of monoclonal antibodies for both basic scientific research and therapeutic application. This Small Business Innovation Research Phase II project aims to establish the applicability, robust manufacturing and characterization protocols of a proposed mutant bacteriophage based carrier platform. This work will establish superior and long-lasting antibody response against weakly immunogenic subunit antigens, while reducing the anti-carrier antibody responses. This project will advance the demonstration of the proposed platform's performance in boosting the immune responses against the target antigens, relative to that of the wild-type bacteriophage and commercially available carrier proteins.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究（SBIR）第二阶段项目的更广泛影响/商业潜力是对结合疫苗领域的贡献，该领域为公共卫生作出了革命性的巨大贡献。一旦开发成功，拟议的平台将供生物技术和制药公司用于开发针对多种抗原（包括癌症和新出现的传染病）的下一代结合疫苗，以改善临床结果。除了疫苗之外，该平台还为基础科学研究和治疗应用的单克隆抗体的产生提供了一个极好的起点。该小型企业创新研究二期项目旨在建立拟议的基于突变噬菌体的载体平台的适用性，稳健的制造和表征方案。这项工作将建立针对弱免疫原性亚单位抗原的优越和持久的抗体反应，同时减少抗载体抗体反应。与野生型噬菌体和市售载体蛋白相比，该项目将推进所提出的平台在增强针对目标抗原的免疫反应方面的表现。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。